Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com



Growth: Bad revenue growth rate -2.6%, there is slowdown compared to average historical growth rates 9.1%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -15.6%

Profitability: LTM EBITDA margin is positive, +23.7%. On average the margin is decreasing unsteadily. Gross margin is high, +54.6%. In the last quarter the company beat the estimated EPS, +4.4%. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.19 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 1.9%. Free cash flow yield -1.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 26.0% higher than minimum and 19.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.9x by EV / Sales multiple , the company can be 43.3% overvalued

Insiders: For the last 3 months insiders sold company shares on $6.8 mln (-0.003% of cap.)

Key Financials (Download financials)

Ticker: ABT  postmarket  113.50  (-0.1%)
Share price, USD:  (+0.2%)113.66
year average price 106.50  


year start price 101.26 2023-03-31

min close price 90.19 2023-10-12

max close price 120.96 2024-03-08

current price 113.66 2024-03-29
Common stocks: 1 746 881 140

Dividend Yield:  1.9%
FCF Yield LTM: -1.0%
EV / LTM EBITDA: 21.9x
EV / EBITDA annualized: 21.3x
Last revenue growth (y/y):  -2.6%
Last growth of EBITDA (y/y):  -7.0%
Historical revenue growth:  9.1%
Historical growth of EBITDA:  15.2%
EV / Sales: 5.2x
Margin (EBITDA LTM / Revenue): 23.7%
Fundamental value created in LTM:
Market Cap ($m): 198 551
Net Debt ($m): 8 677
EV (Enterprise Value): 207 228
Price to Book: 5.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-27Zacks Investment Research

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark

2024-03-26Zacks Investment Research

Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know

2024-03-26Zacks Investment Research

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

2024-03-26InvestorPlace

Winning Over Wall Street: 3 Stocks Earning Overwhelming Analyst Approval

2024-03-25Zacks Investment Research

Abbott (ABT) Expands in Canada With First Eterna SCS Use

2024-03-22The Motley Fool

Want Decades of Passive Income? 2 Stocks to Buy Now.

2024-03-21InvestorPlace

3 Stocks to Buy Right Now for the Coming Recession

2024-03-21InvestorPlace

3 Resilient Stocks to Protect Your Wealth During a Recession

2024-03-20Zacks Investment Research

Abbott (ABT) Stock Slides as Market Rises: Facts to Know Before You Trade

2024-03-19Zacks Investment Research

Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ABT ABT ABT ABT ABT ABT
reportedCurrency USD USD USD USD USD USD
cik 1800.000 1800.000 1800.000 1800.000 1800.000 1800.000
fillingDate 2024-02-16 2023-11-01 2023-08-03 2023-05-04 2023-02-17 2022-11-01
acceptedDate 2024-02-16 16:15:58 2023-11-01 16:07:32 2023-08-03 16:07:28 2023-05-04 16:03:45 2023-02-17 16:09:44 2022-11-01 16:06:19
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 10 241M 10 143M 9 978M 9 747M 10 091M 10 410M
costOfRevenue 4 983M 4 605M 4 483M 4 331M 4 593M 4 629M
grossProfit 5 258M 5 538M 5 495M 5 416M 5 498M 5 781M
grossProfitRatio 0.513 0.546 0.551 0.556 0.545 0.555
researchAndDevelopmentExpenses 690M 672M 715M 654M 725M 782M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2 704M 2 601M 2 740M 2 762M 2 973M 2 731M
otherExpenses 109M 83M 498M 491M 496M 498M
operatingExpenses 3 394M 3 798M 3 953M 3 907M 4 194M 4 011M
costAndExpenses 8 377M 8 403M 8 436M 8 238M 8 787M 8 640M
interestIncome 89M 69M 98M 101M 88M 55M
interestExpense 235M 166M 61M 52M 66M 141M
depreciationAndAmortization 813M 824M 674M 602M 564M 944M
ebitda 2 677M 2 593M 2 216M 2 111M 1 868M 2 714M
ebitdaratio 0.261 0.256 0.222 0.217 0.185 0.261
operatingIncome 1 864M 1 769M 1 542M 1 509M 1 304M 1 770M
operatingIncomeRatio 0.182 0.174 0.155 0.155 0.129 0.170
totalOtherIncomeExpensesNet -69M -98M 94M 53M 16M -12M
incomeBeforeTax 1 795M 1 671M 1 636M 1 562M 1 320M 1 758M
incomeBeforeTaxRatio 0.175 0.165 0.164 0.160 0.131 0.169
incomeTaxExpense 201M 235M 261M 244M 287M 323M
netIncome 1 594M 1 436M 1 375M 1 318M 1 033M 1 435M
netIncomeRatio 0.156 0.142 0.138 0.135 0.102 0.138
eps 0.920 0.820 0.790 0.760 0.590 1.150
epsdiluted 0.910 0.820 0.780 0.750 0.590 0.810
weightedAverageShsOut 1 734M 1 736M 1 739M 1 738M 1 738M 1 248M
weightedAverageShsOutDil 1 748M 1 748M 1 750M 1 752M 1 754M 1 764M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ABT ABT ABT ABT ABT ABT
reportedCurrency USD USD USD USD USD USD
cik 1800.000 1800.000 1800.000 1800.000 1800.000 1800.000
fillingDate 2024-02-16 2023-11-01 2023-08-03 2023-05-04 2023-02-17 2022-11-01
acceptedDate 2024-02-16 16:15:58 2023-11-01 16:07:32 2023-08-03 16:07:28 2023-05-04 16:03:45 2023-02-17 16:09:44 2022-11-01 16:06:19
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 6 896M 6 709M 7 835M 9 882M 9 882M 9 594M
shortTermInvestments 383M 338M 320M 288M 288M 313M
cashAndShortTermInvestments 7 279M 7 047M 8 155M 10 170M 10 170M 9 907M
netReceivables 6 565M 8 967M 8 479M 8 172M 8 881M 6 408M
inventory 6 570M 6 650M 6 871M 6 173M 6 173M 5 734M
otherCurrentAssets 2 256M 8 967M 8 479M 8 881M 2 663M 2 796M
totalCurrentAssets 22 670M 22 664M 23 505M 25 224M 25 224M 24 845M
propertyPlantEquipmentNet 11 276M 9 552M 9 449M 9 162M 9 162M 8 689M
goodwill 23 679M 23 277M 23 258M 22 799M 22 799M 22 284M
intangibleAssets 8 815M 9 282M 9 834M 10 454M 10 454M 10 850M
goodwillAndIntangibleAssets 32 494M 32 559M 33 092M 33 253M 33 253M 33 134M
longTermInvestments 799M 788M 799M 766M 766M 764M
taxAssets 0 6 527M 6 509M 6 033M 6 033M 5 369M
otherNonCurrentAssets 5 975M 0 0 0 0 0
totalNonCurrentAssets 50 544M 49 426M 49 849M 49 214M 49 214M 47 956M
otherAssets 0 0 0 0 0 0
totalAssets 73 214M 72 090M 73 354M 74 438M 74 438M 72 801M
accountPayables 4 295M 3 961M 4 211M 4 607M 4 607M 4 133M
shortTermDebt 1 325M 1 051M 2 284M 2 251M 2 251M 1 117M
taxPayables 492M 318M 273M 343M 343M 394M
deferredRevenue 1 447M 318M 273M 0 0 0
otherCurrentLiabilities 6 774M 7 712M 7 582M 8 631M 8 631M 8 115M
totalCurrentLiabilities 13 841M 13 042M 14 350M 15 489M 15 489M 13 365M
longTermDebt 13 599M 14 477M 14 562M 14 522M 15 465M 15 297M
deferredRevenueNonCurrent 949M -6 877M -7 038M -7 417M 0 0
deferredTaxLiabilitiesNonCurrent 1 218M 6 877M 7 038M 7 522M 991M 0
otherNonCurrentLiabilities 4 780M 6 877M 7 038M 7 417M 5 588M 18 302M
totalNonCurrentLiabilities 20 546M 21 354M 21 600M 22 044M 22 044M 23 552M
otherLiabilities 0 0 0 -971M 0 0
capitalLeaseObligations 949M 0 0 0 943M 8 255M
totalLiabilities 34 387M 34 396M 35 950M 36 562M 37 533M 36 917M
preferredStock 0 0 0 0 0 0
commonStock 24 869M 24 727M 24 612M 24 709M 24 709M 24 560M
retainedEarnings 37 554M 36 920M 36 355M 35 868M 35 257M 35 115M
accumulatedOtherComprehensiveIncomeLoss -7 839M -8 480M -8 071M -8 051M -8 051M -9 445M
othertotalStockholdersEquity -15 981M -15 686M -15 722M 21 693M -15 229M -14 555M
totalStockholdersEquity 38 603M 37 481M 37 174M 74 219M 36 686M 35 675M
totalEquity 38 827M 37 694M 37 404M 74 219M 36 686M 35 675M
totalLiabilitiesAndStockholdersEquity 73 214M 72 090M 73 354M 74 438M 74 438M 72 801M
minorityInterest 224M 213M 230M 222M 219M 0
totalLiabilitiesAndTotalEquity 73 214M 72 090M 73 354M 74 438M 74 438M 72 801M
totalInvestments 1 182M 1 126M 1 119M 1 054M 1 054M 1 077M
totalDebt 15 873M 15 528M 16 846M 16 773M 17 716M 16 414M
netDebt 8 977M 8 819M 9 011M 6 891M 7 834M 6 820M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ABT ABT ABT ABT ABT ABT
reportedCurrency USD USD USD USD USD USD
cik 1800.000 1800.000 1800.000 1800.000 1800.000 1800.000
fillingDate 2024-02-16 2023-11-01 2023-08-03 2023-05-04 2023-02-17 2022-11-01
acceptedDate 2024-02-16 16:15:58 2023-11-01 16:07:32 2023-08-03 16:07:28 2023-05-04 16:03:45 2023-02-17 16:09:44 2022-11-01 16:06:19
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 1 588M 1 436M 1 375M 1 318M 1 033M 1 435M
depreciationAndAmortization 813M 824M 800M 806M 807M 815M
deferredIncomeTax -1 377M 0 0 0 0 0
stockBasedCompensation 114M 117M 132M 281M 115M 123M
changeInWorkingCapital 391M -321M -444M -186M 114M 336M
accountsReceivables 68M -461M -196M 233M 341M 530M
inventory 295M 140M -248M -419M -189M -194M
accountsPayables -1 345M 179M 0 0 420M 0
otherWorkingCapital 1 373M -179M 0 186M -458M 0
otherNonCashItems 1 509M -179M -660M -1 076M 257M 71M
netCashProvidedByOperatingActivities 3 038M 1 877M 1 203M 1 143M 2 326M 2 780M
investmentsInPropertyPlantAndEquipment -755M -560M -507M -380M -610M -467M
acquisitionsNet 0 -51M 0 0 -235M 0
purchasesOfInvestments -114M -38M 0 -86M -203M 0
salesMaturitiesOfInvestments 43M 38M 0 0 152M 0
otherInvestingActivites 2M -23M -706M 4M 264M -17M
netCashUsedForInvestingActivites -824M -634M -1 213M -462M -632M -484M
debtRepayment -939M -1 445M -2M 0 -549M -1 000 000
commonStockIssued 34M 56M 0 0 0 0
commonStockRepurchased -259M -2M -426M -540M -685M -798M
dividendsPaid -888M -888M -890M -890M -823M -826M
otherFinancingActivites 0 -61M 29M 20M 600M 82M
netCashUsedProvidedByFinancingActivities -2 052M -2 340M -1 289M -1 410M -1 457M -1 543M
effectOfForexChangesOnCash 25M -29M -27M 8M 51M -96M
netChangeInCash 187M -1 126M -1 326M -721M 288M 657M
cashAtEndOfPeriod 6 896M 6 709M 7 835M 9 161M 9 882M 9 594M
cashAtBeginningOfPeriod 6 709M 7 835M 9 161M 9 882M 9 594M 8 937M
operatingCashFlow 3 038M 1 877M 1 203M 1 143M 2 326M 2 780M
capitalExpenditure -755M -560M -507M -380M -610M -467M
freeCashFlow 2 283M 1 317M 696M 763M 1 716M 2 313M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-01-24 ET (fiscal 2023 q4)
2023 q3
2023-10-18 ET (fiscal 2023 q3)
2023 q2
2023-07-20 ET (fiscal 2023 q2)
2023 q1
2023-04-19 ET (fiscal 2023 q1)
2022 q4
2023-01-25 ET (fiscal 2022 q4)
2022 q3
2022-10-19 ET (fiscal 2022 q3)
2022 q2
2022-07-20 ET (fiscal 2022 q2)
2022 q1
2022-04-20 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-01-25 14:00 ET
Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+
2024-01-24 12:30 ET
Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook
2024-01-18 14:00 ET
Abbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
2024-01-03 14:00 ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
2023-12-18 14:00 ET
Abbott to Present at J.P. Morgan Healthcare Conference
2023-12-15 16:25 ET
Abbott Increases Quarterly Dividend for 52nd Consecutive Year
2023-11-13 14:00 ET
Late-Breaking Data Show an Aspirin-Free Medication Regimen Benefits People with Abbott's HeartMate 3™ Heart Pump
2023-11-08 11:00 ET
Participants in Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes
2023-11-02 13:00 ET
Abbott Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV
2023-11-01 12:28 ET
Abbott and Sherri Shepherd: Millions Not Using Affordable Diabetes Technology
2023-10-31 12:00 ET
Abbott and Damar Hamlin Team Up to Build Heart Health Community with New HeartMates Program
2023-10-26 13:00 ET
Ninety-One Percent of Young Adults With Student Loans Say Financial Stress is Impacting Their Wellness -- Abbott Launches Blueprint of Award-Winning Program to Help Companies Tackle This Problem
2023-10-25 18:30 ET
Late-Breaking Data Show Esprit™ BTK Drug-Eluting Resorbable Scaffold Reduces Chronic Limb-Threatening Ischemia Progression Compared to the Standard of Care
2023-10-24 22:18 ET
Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves
2023-10-18 11:30 ET
Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range
2023-09-27 13:00 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2023-09-22 12:48 ET
Abbott Completes Acquisition of Bigfoot Biomedical
2023-09-21 16:02 ET
Abbott Declares 399th Consecutive Quarterly Dividend
2023-09-20 12:00 ET
Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets
2023-09-11 12:30 ET
Less Is More: Abbott’s Approach to Packaging Innovation
2023-09-05 20:30 ET
Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes
2023-07-20 11:30 ET
Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business
2023-07-05 13:00 ET
Abbott Receives FDA Approval for World's First Dual Chamber Leadless Pacemaker
2023-06-29 13:00 ET
Abbott Hosts Conference Call for Second-Quarter Earnings
2023-06-22 13:00 ET
Abbott's FreeStyle Libre® 2 Receives National Reimbursement in France for All People with Diabetes Who Use Insulin¹
2023-06-09 14:55 ET
Abbott Declares 398th Consecutive Quarterly Dividend
2023-05-31 13:00 ET
Abbott, Real Madrid and the Real Madrid Foundation Band Together to 'Beat Malnutrition' Globally Through New Campaign
2023-05-24 13:00 ET
European Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations
2023-05-20 13:18 ET
Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints
2023-05-19 13:00 ET
Abbott Receives FDA Approval for TactiFlex™ Ablation Catheter for Treatment of Abnormal Heart Rhythm
2023-05-18 13:00 ET
Abbott Receives FDA Clearance for Assert-IQ™ Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term
2023-05-16 13:00 ET
Abbott Receives FDA Approval for Its Spinal Cord Stimulation Systems to Treat Chronic Back Pain in People Who Have Limited Surgical Options
2023-05-11 13:00 ET
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative
2023-04-27 20:10 ET
Abbott Completes Acquisition of Cardiovascular Systems, Inc.
2023-04-25 13:00 ET
Abbott's Life Support System Receives New FDA Clearances to Help Doctors Treat More Critically Ill Patients
2023-04-20 13:00 ET
Abbott and New Global Consortium Partnership Address Viral Outbreaks Caused by Climate Change
2023-04-19 11:15 ET
Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business
2023-04-17 12:00 ET
Abbott's FreeStyle Libre® Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare Beneficiaries
2023-04-14 13:00 ET
FDA Clears Reader for Abbott's FreeStyle Libre® 3 System
2023-03-29 13:00 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2023-03-23 13:00 ET
Don't Mess with Your 'Melon': Abbott and the Brain Injury Association of America Urge 'If You Hit Your Head, Get it Checked' in New Public Service Announcement
2023-03-07 14:00 ET
Abbott Receives FDA Clearance for First Commercially Available Lab-based Blood Test to Help Evaluate Concussion
2023-03-06 12:00 ET
U.S. FDA Clears Abbott's FreeStyle Libre® 2 and FreeStyle Libre® 3 Sensors for Integration with Automated Insulin Delivery Systems
2023-03-05 14:07 ET
Late-Breaking Data from Landmark COAPT™ Trial Show Long-Term Benefits of Abbott's MitraClip™ Device
2023-03-04 15:41 ET
New Data Show Superiority of Abbott's TriClip™ Device Compared to Medical Therapy for Tricuspid Regurgitation
2023-02-28 14:00 ET
Late-Breaking Data Reinforce Benefits of Abbott's Minimally Invasive Heart Devices
2023-02-17 17:26 ET
Abbott Declares 397th Consecutive Quarterly Dividend
2023-02-08 23:05 ET
Abbott to Acquire Cardiovascular Systems, Inc.
2023-01-26 14:00 ET
FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
2023-01-25 12:30 ET
Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
2023-01-17 14:00 ET
Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis
2023-01-07 02:00 ET
Abbott, Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation
2023-01-04 14:00 ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
2022-12-21 14:00 ET
Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany
2022-12-20 14:00 ET
Abbott to Present at J.P. Morgan Healthcare Conference
2022-12-19 14:00 ET
Abbott Launches the World's Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain
2022-12-13 13:30 ET
Abbott and the Brain Injury Association of America launch Concussion Awareness Now coalition; team up with Rebel Wilson to raise awareness on seriousness of concussions
2022-12-09 15:48 ET
Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth
2022-11-17 14:00 ET
Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology
2022-10-28 13:00 ET
Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation
2022-10-19 11:30 ET
Abbott Reports Third-Quarter 2022 Results and Raises Full-Year EPS Guidance
2022-10-12 13:42 ET
Abbott and The Home Edit Redesign the Medicine Cabinet to Help People Prepare for the Upcoming Virus Season
2022-10-06 13:00 ET
New Study Published in The New England Journal of Medicine Demonstrates Abbott's FreeStyle Libre® 2 System Has Positive Impacts on Glucose Levels and Quality of Life
2022-09-28 13:00 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2022-09-17 18:45 ET
Late-Breaking Data Show Breadth of Abbott's Minimally Invasive Structural Heart Technologies
2022-09-15 16:56 ET
Abbott Declares 395th Consecutive Quarterly Dividend
2022-09-08 13:00 ET
Three-Year Data on World's Smallest Heart Device Show Benefits of Fixing Holes in Newborn Hearts Without Surgery
2022-08-29 13:00 ET
New Data Show Abbott's HeartMate 3™ Heart Pump Extends Life Beyond Five Years for Advanced Heart Failure Patients
2022-08-23 13:00 ET
FDA Approves Abbott's New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions
2022-08-11 13:00 ET
New Study Shows Abbott's Blood Test for Concussion Could Predict Outcomes from Brain Injury and Inform Treatment Interventions
2022-08-04 20:10 ET
Abbott and WeightWatchers Partner to Support People Living with Diabetes in Attaining their Health Goals
2022-07-20 11:30 ET
Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance
2022-07-12 13:00 ET
Abbott Receives FDA's Breakthrough Device Designation to Explore Use of Deep Brain Stimulation to Manage Severe Depression
2022-06-29 13:00 ET
Abbott Hosts Conference Call for Second-Quarter Earnings
2022-06-10 15:26 ET
Abbott Declares 394th Consecutive Quarterly Dividend
2022-06-05 13:00 ET
Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor
2022-06-03 13:00 ET
Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System
2022-05-31 12:00 ET
Abbott's FreeStyle Libre® 3 Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor
2022-05-27 16:05 ET
Diandra “Fu” Debrosse Zimmermann Becomes First Black Woman Ever Appointed to Lead a Multidistrict Litigation with Co-Lead Counsel Selection in Baby Formula MDL
2022-05-24 21:11 ET
Abbott to Release EleCare® Amino Acid-based Formulas to Help Meet Critical Patient Need
2022-05-19 13:15 ET
New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies
2022-05-16 20:22 ET
Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility
2022-05-11 13:00 ET
Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials
2022-05-04 13:00 ET
Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
2022-04-29 20:35 ET
Abbott to Release Metabolic Nutrition Formulas
2022-04-29 13:00 ET
Study Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott's Ablation Device Remain Symptom-Free for at Least 15 Months
2022-04-28 13:00 ET
Abbott Strengthens Left Atrial Appendage Closure Leadership With U.S. Availability of Amplatzer™ Steerable Delivery Sheath for the Company's Amulet™ Device
2022-04-28 11:00 ET
New Analysis Shows that Abbott's FreeStyle Libre® System Provides Similar and Sustained Reductions in Glucose Levels for People with Both Type 1 and Type 2 Diabetes
2022-04-27 12:00 ET
Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes
2022-04-26 13:00 ET
Abbott Recommends Rejection of Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
2022-04-25 13:00 ET
Abbott Strengthens Its Connected Care Technologies with Latest NeuroSphere™ myPath™ Digital Health App
2022-04-20 11:30 ET
Abbott Reports First-Quarter 2022 Results
2022-04-04 13:00 ET
Abbott Receives FDA Approval for Aveir™ VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms
2022-03-30 11:30 ET
Abbott and LISC Team Up to Address Diversity and Equity Gaps in the Healthcare Industry Supply Chain
2022-03-28 13:00 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2022-03-24 13:00 ET
Abbott's FreeStyle® Libre is First and Only CGM System to Gain Expanded Reimbursement in Japan to Include All People with Diabetes Who Use Insulin
2022-02-21 14:00 ET
Abbott's CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure
2022-02-18 16:26 ET
Abbott Declares 393rd Consecutive Quarterly Dividend
2022-02-17 22:11 ET
Abbott Voluntarily Recalls Powder Formulas Manufactured at One Plant
2022-02-07 14:00 ET
Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial
2022-01-26 12:30 ET
Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast
2022-01-12 14:00 ET
Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms
2022-01-06 18:15 ET
Abbott Announces Future of Biowearables at Consumer Electronics Show
2022-01-04 22:00 ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
2022-01-04 14:00 ET
Abbott's Proclaim™ XR Spinal Cord Stimulation System Now Offers Expanded MRI Compatibility in U.S.
2021-12-21 14:00 ET
Abbott to Present at J.P. Morgan Healthcare Conference
2021-12-10 19:00 ET
Abbott Names Robert B. Ford Chairman of the Board; Miles D. White to Retire as Executive Chairman
2021-12-10 18:00 ET
Abbott Increases Quarterly Dividend for 50th Consecutive Year
2021-11-16 18:00 ET
Abbott Launches Similac® 360 Total Care® with Exclusive Blend of Five HMO Prebiotics and Designed to Support the Immune System, Digestive Health and Brain Development
2021-11-15 15:48 ET
Abbott Achieves Highest Score in Its Industry for the Ninth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
2021-11-12 14:00 ET
Abbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial
2021-11-09 14:00 ET
Abbott and the American Diabetes Association® Launch First-of-Its-Kind Community Initiative in Columbus, Ohio, to Advance Access to Diabetes Care and Technology
2021-11-03 13:00 ET
Abbott Launches New Initiative to Drive Diversity in Medical Research and Improve Care Among Under-Represented Populations
2021-10-20 11:30 ET
Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
2021-10-18 13:22 ET
Jason Sudeikis Joins Abbott, Real Madrid at New York Stock Exchange to Support Children's Health
2021-10-18 11:00 ET
Abbott and Real Madrid Team Up to Support the Health and Nutrition of Children Globally
2021-09-30 13:48 ET
Abbott Commits to Reducing Malnutrition Globally with Launch of Abbott Center for Malnutrition Solutions
2021-09-23 13:00 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2021-09-20 13:00 ET
Abbott Receives FDA Approval for Minimally Invasive Portico™ with FlexNav™ TAVR System to Treat Patients with Aortic Valve Disease
2021-09-15 16:46 ET
Abbott Declares 391st Consecutive Quarterly Dividend
2021-09-02 13:30 ET
Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC
2021-08-30 15:55 ET
Late-Breaking Data Shows Abbott's Amplatzer™ Amulet™ Occluder Offers Superior Left Atrial Appendage Closure Compared to Watchman‡ Device for People With Atrial Fibrillation at Risk of Stroke
2021-08-27 12:46 ET
GUIDE-HF Study Data Show Abbott's CardioMEMS™ Device Can Improve Care for More Patients with Heart Failure
2021-08-18 14:46 ET
Podcast: How to Find STEM Success? Learn to Pivot.
2021-08-16 16:06 ET
Strengthening Resilience in Vulnerable Communities
2021-08-16 12:00 ET
Abbott's Amplatzer™ Amulet™ Device Approved by FDA to Treat People With Atrial Fibrillation at Risk of Stroke
2021-08-13 13:51 ET
Abbott's Freestyle® Libre 2 IOS App Cleared In U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management
2021-08-09 12:01 ET
A Workplace Where Collaboration = Innovation
2021-08-06 12:26 ET
A Convergence of Challenges: Addressing the Devastating Impact of Chronic Disease on Communities in Crisis
2021-08-04 14:11 ET
Broader Access is Vital to the Future of Testing and Healthcare Innovation
2021-08-03 13:00 ET
Abbott Receives FDA Clearance for its Imaging Technology Using Artificial Intelligence for Vessels in the Heart
2021-08-02 13:00 ET
Abbott's FreeStyle® Libre 2 iOS App Cleared in U.S., Providing a Seamless Digital Experience to Simplify Diabetes Management
2021-07-29 13:00 ET
New Study: Half of Americans Living with Diabetes May be Consuming Less Than the Recommended Amount of Protein, which is Associated with Greater Physical Limitations
2021-07-23 15:42 ET
Building Trust and Improving Care in Underserved Communities
2021-07-22 11:15 ET
Abbott Reports Second-Quarter 2021 Results
2021-07-15 13:16 ET
Delivering Long-Term Impact: Abbott's 2020 Sustainability Report
2021-06-30 13:00 ET
Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
2021-06-25 15:30 ET
Late-Breaking Data Demonstrate Abbott's FreeStyle® Libre System Supports Health Equity for Millions of Americans Living with Diabetes
2021-06-25 13:00 ET
Abbott Hosts Conference Call for Second-Quarter Earnings
2021-06-24 13:00 ET
People Who Exercise Intensely Could Improve Recovery by Adjusting Their Hydration Habits
2021-06-23 12:11 ET
Abbott Earns First-of-Its-Kind Recommendation for High School STEM Interns to Receive College Credit
2021-06-22 11:00 ET
Abbott Earns First-of-its-Kind Recommendation for High School STEM Interns to Receive College Credit
2021-06-11 15:19 ET
Abbott Declares 390th Consecutive Quarterly Dividend
2021-06-03 11:00 ET
Abbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump
2021-06-01 12:00 ET
Abbott Issues Updated 2021 Outlook
2021-05-17 13:00 ET
Abbott Receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosis
2021-05-06 13:00 ET
Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial
2021-04-20 11:30 ET
Abbott Reports First-Quarter 2021 Results
2021-04-19 12:30 ET
Abbott Begins Shipping BinaxNOW™ COVID-19 Ag Self Test to Retailers Today
2021-04-12 12:00 ET
World's Fastest Marathoner Eliud Kipchoge Uses Abbott's Libre Sense at NN Mission Marathon Qualifier Race for the Olympic Games
2021-04-08 13:00 ET
Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair
2021-04-06 13:00 ET
Abbott's XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients
2021-04-01 03:06 ET
Abbott's BinaxNOW™ Rapid Antigen Self Test Receives FDA Emergency Use Authorization for Asymptomatic, Over-the-Counter, Non-Prescription, Multi-Test Use
2021-03-29 14:30 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2021-03-11 14:00 ET
Abbott Announces its Pandemic Defense Coalition: A Global Network of Expert Collaborators Designed To Help Prevent Future Pandemics, Currently Searching for COVID-19 Variants
2021-03-08 14:00 ET
Abbott Introduces NeuroSphere™ Virtual Clinic, First-of-its-Kind Remote Neuromodulation Patient-Care Technology in the U.S.
2021-03-05 14:00 ET
Abbott Receives FDA EUA for Laboratory PCR Assay That Detects and Differentiates SARS-CoV-2, Flu A, Flu B and RSV in One Test - and FDA EUA for Asymptomatic Usage of Alinity m COVID-19 Test
2021-03-02 12:45 ET
Abbott Researchers Find Rare Group of People With Controlled HIV Who Could Be a Key To Unlocking Cure
2021-02-19 18:26 ET
Abbott Declares 389th Consecutive Quarterly Dividend
2021-01-27 12:30 ET
Abbott Reports Fourth-Quarter 2020 Results; Issues Strong Double-Digit Growth Forecast for 2021
2021-01-26 12:45 ET
Abbott's Panbio Rapid Antigen Test Receives CE Mark for Asymptomatic Screening and Self-Administered Sample Collection with Nasal Swab
2021-01-20 12:45 ET
Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip™ Device
2021-01-14 14:00 ET
Abbott to Launch the NeuroSphere™ myPath™ Digital Health App Designed to Track and Report Pain Relief in Chronic Pain Patients With Physicians Prior to Device Implant
2021-01-12 14:00 ET
Abbott Announces Fulfillment of Federal Government Purchase of 150 Million BinaxNOW™ COVID-19 Rapid Tests and Is Now Ready to Support Commercial Distribution
2021-01-11 14:00 ET
Abbott Receives FDA 510(k) Clearance for the First Rapid Handheld Blood Test for Concussions
2021-01-06 14:00 ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
2020-12-22 14:00 ET
As Vaccines Roll Out, Americans See COVID-19 Testing as Important Partner
2020-12-18 14:00 ET
Abbott to Present at J.P. Morgan Healthcare Conference
2020-12-17 21:52 ET
FDA Approves Labeling Update for Abbott's HeartMate 3 Heart Pump for use in Pediatric Patients
2020-12-16 17:55 ET
Abbott's BinaxNOW COVID-19 Rapid Test Receives FDA Emergency Use Authorization for First Virtually Guided, At-Home Rapid Test Using eMed's Digital Health Platform
2020-12-15 14:00 ET
Abbott Receives CE Mark for its COVID-19 IgG Quantitative Antibody Blood Test
2020-12-14 14:00 ET
Abbott Develops New Pedialyte® Hydration Solution to Help Support Immune Health
2020-12-11 16:00 ET
Abbott Increases Quarterly Dividend by 25%
2020-12-02 13:00 ET
Abbott's FreeStyle Libre 2 Now Approved for Adults and Children with Diabetes in Canada, Featuring Unsurpassed 14-Day Accuracy and Optional Alarms
2020-11-18 14:00 ET
Abbott Becomes First Anchor Sponsor of American Diabetes Association's Health Equity Now Initiative to Advance Access to Care and Technology for People with Diabetes
2020-11-16 15:20 ET
Abbott Named Industry Sustainability Leader for the Eighth Year in a Row on the Dow Jones Sustainability Index (DJSI)
2020-11-10 14:00 ET
Abbott Announces the U.S. Launch of the IonicRF™ Generator for Use in Patients Living With Chronic Pain
2020-10-30 13:00 ET
Abbott Wins Prestigious Prix Galien USA Award for First-of-its-Kind MitraClip™ Device
2020-10-21 11:30 ET
Abbott Reports Third-Quarter 2020 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance
2020-10-19 11:15 ET
Improved Mental and Physical Condition is Directly Linked to Nutrition, Study Shows
2020-10-12 13:00 ET
Abbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test
2020-10-07 12:00 ET
Abbott Releases ID NOW™ COVID-19 Interim Clinical Study Results from 1,003 People to Provide the Facts on Clinical Performance and to Support Public Health
2020-09-28 13:00 ET
Abbott's FreeStyle® Libre 3 System Receives CE Mark - Features World's Smallest, Thinnest Sensor with Best-in-Class Performance at the Same Low Cost for People with Diabetes
2020-09-21 13:02 ET
Abbott Receives CE Mark for Next-Generation MitraClip™ Heart Valve Repair Device to Treat Mitral Regurgitation
2020-09-21 13:00 ET
Abbott Hosts Conference Call for Third-Quarter Earnings
2020-09-17 15:39 ET
Abbott Declares 387th Consecutive Quarterly Dividend
2020-09-17 13:00 ET
Abbott Introduces Libre Sense Glucose Sport Biosensor in Europe, World's First Glucose Biosensor Designed for Athletes
2020-09-03 13:00 ET
Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold
2020-09-01 13:00 ET
Abbott's FreeStyle® Libre 2 iCGM System Now Available to Medicare Beneficiaries
2020-08-26 22:30 ET
Abbott's Fast, $5, 15-Minute, Easy-to-Use COVID-19 Antigen Test Receives FDA Emergency Use Authorization; Mobile App Displays Test Results to Help Our Return to Daily Life; Ramping Production to 50 Million Tests a Month
2020-08-04 13:00 ET
Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation
2020-07-23 13:00 ET
Abbott Receives FDA Approval for iOS-Compatible App Allowing People Living With Chronic Pain and Movement Disorders to Personalize Therapy Via Their Mobile Device
2020-07-16 11:30 ET
Abbott Reports Second-Quarter 2020 Results, Exceeds Analysts' Expectations
2020-07-13 20:15 ET
Abbott Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences
2020-07-06 11:30 ET
Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring
2020-01-13 14:00 ET
Abbott to Initiate Trial to Study MitraClip as an Option for Moderate Surgical Risk Patients
2020-01-07 15:04 ET
FDA Approves Less Invasive Surgical Approach for Abbott's Heart Pump to Help Patients Avoid Open Heart Surgery
2019-12-13 15:39 ET
Abbott Raises Quarterly Dividend 12.5%, Increasing Payouts for 48 Straight Years
2019-11-13 12:45 ET
Abbott Announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020
2019-11-06 13:37 ET
Abbott Announces Discovery of New Strain of HIV, Keeping Global Health Community a Step Ahead of the Virus
2019-10-21 13:00 ET
The Australian Red Cross Blood Service Selects Abbott's Alinity s Solution for Blood and Plasma Screening
2019-04-18 13:00 ET
Latin American Countries Offer Unique Benefits to Cannabis Cultivators
2019-04-11 19:16 ET
Abbott and the Abbott Fund Support Relief Efforts for Cyclone Idai
2019-03-20 13:00 ET
Abbott Hosts Conference Call for First-Quarter Earnings
2019-03-19 12:00 ET
Abbott Announces CE Mark for Alinity™ m Diagnostics System and Assays, the Latest in Molecular Technology, to Help Deliver Critical Test Results and Benefits to Patients

SEC forms

Show financial reports only

SEC form 10
2024-02-16 00:00 ET
Abbott published news for 2023 q4
SEC form 8
2024-01-24 07:36 ET
Abbott published news for 2023 q4
SEC form 8
2024-01-24 07:36 ET
Abbott published news for 2023 q4
SEC form 10
2023-11-01 00:00 ET
Abbott reported for 2023 q3
SEC form 8
2023-10-18 07:37 ET
Abbott published news for 2023 q3
SEC form 10
2023-08-03 00:00 ET
Abbott reported for 2023 q2
SEC form 6
2023-07-20 08:29 ET
Abbott published news for 2023 q2
SEC form 8
2023-07-20 00:00 ET
Abbott published news for 2023 q2
SEC form 6
2023-06-23 16:07 ET
Abbott published news for 2023 q1
SEC form 6
2023-06-12 10:32 ET
Abbott published news for 2023 q1
SEC form 6
2023-06-09 16:05 ET
Abbott published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
Abbott reported for 2023 q1
SEC form 8
2023-04-19 00:00 ET
Abbott published news for 2023 q1
SEC form 10
2023-02-17 00:00 ET
Abbott reported for 2022 q4
SEC form 8
2023-01-25 00:00 ET
Abbott reported for 2022 q4
SEC form 10
2022-11-01 00:00 ET
Abbott reported for 2022 q3
SEC form 8
2022-10-19 00:00 ET
Abbott reported for 2022 q3
SEC form 10
2022-08-02 00:00 ET
Abbott reported for 2022 q2
SEC form 8
2022-07-20 00:00 ET
Abbott published news for 2022 q2
SEC form 10
2022-05-03 00:00 ET
Abbott reported for 2022 q1
SEC form 8
2022-04-20 00:00 ET
Abbott reported for 2022 q1
SEC form 10
2022-02-18 00:00 ET
Abbott published news for 2021 q4
SEC form 8
2022-01-26 00:00 ET
Abbott published news for 2021 q4
SEC form 10
2021-11-03 00:00 ET
Abbott published news for 2021 q3
SEC form 8
2021-10-20 00:00 ET
Abbott published news for 2021 q3
SEC form 10
2021-08-04 00:00 ET
Abbott published news for 2021 q2
SEC form 8
2021-07-22 00:00 ET
Abbott published news for 2021 q2
SEC form 10
2021-05-05 00:00 ET
Abbott published news for 2021 q1
SEC form 8
2021-04-20 00:00 ET
Abbott published news for 2021 q1